Derived from each individual’s tumor, Prophage Series therapeutic vaccines contain the ‘antigenic fingerprint’ of the patient’s particular cancer and are designed to direct the body’s immune system to specifically target and destroy cancer cells bearing this fingerprint. Prophage Series vaccines, based on Agenus’ heat shock protein platform technology, are intended to leave healthy tissue unaffected and limit the debilitating side effects typically associated with traditional cancer treatments such as chemotherapy and radiation therapy.

Each patient’s cancer is unique. Random mutations and tens of thousands of genes mean even within the same type of cancer, no two individuals’ cancers are biologically the same. Taking these factors into account, the Prophage Series vaccines are developed from the best biological representation of a patient’s cancer and created individually for each patient from their own tumor.

The Prophage Series vaccines are currently being studied in both newly diagnosed and recurrent GBM. GBM is the most aggressive primary malignant brain tumor and accounts for the majority of diagnoses of malignant cancers of the brain.